Health care stocks were declining Thursday afternoon, with the NYSE Health Care Index shedding 0.4% and the Health Care Select Sector SPDR Fund (XLV) down 0.3%.
The iShares Biotechnology ETF (IBB) fell 1.1%.
In corporate news, Eli Lilly's (LLY) tirzepatide injection products Zepbound and Mounjaro are no longer in shortage, the US Food and Drug Administration said Thursday. Eli Lilly shares were down 0.8%.
Omeros (OMER) shares surged 44% after it said Thursday that its trial of narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy met its primary endpoint in overall survival.
Aquestive Therapeutics (AQST) shares jumped 5.6% after it said Thursday that its Libervant buccal film has received seven years of orphan drug exclusivity from the US Food and Drug Administration to treat seizure clusters in patients with epilepsy ages two to five.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。